Guidelines for economic evaluations in italy: Recommendations from the italian group of pharmacoeconomic studies

Therapeutic Innovation & Regulatory Science

Volumn 35, Issue 1, 2000, Pages 189-201

  Capri, Stefano ^a,b   Ceci, Adriana ^b   Terranova, Lorenzo ^c   Merlo, Franco ^d   Mantovani, Lorenzo ^e  

^a UNIVERSITY OF PAVIA   (Italy)

^b BETA Biomedical Technology Assessement   (Italy)

^c Farmindustria   (Italy)

^d UNIVERSITY OF GENOA   (Italy)

^e UNIVERSITY OF MILAN   (Italy)

Author keywords

Italian Group for Pharmacoeconomic Studies; Italy; Pharmacoeconomics

Indexed keywords

EID: 84996147125     PISSN: 21684790     EISSN: None     Source Type: Journal    
DOI: 10.1177/009286150103500122     Document Type: Article

References (44)

1. CIPE, Inter-Ministerial Committee for Economic Planning. Identifying criteria for contracting on the price of innovative medicines. Decree of January 30, 1997. Official Gazette. May 3, 1997.
2. Joint Government/Pharmaceutical Industry Working Party. UK guidance on good practice in the conduct of economic evaluation of medicines. Br J Med Econ. 1994; 7: 63–64.
3. Rovira J, Antonanzas F. Economic analysis of health technologies and programs: a Spanish proposal for methodological standardization. Pharmacoecon. 1995; 7: 1–6.
4. Collège des Economistes de la Santé. Guidelines and Recommendations for French Pharmaco-economic studies. CES. April 1997.
5. Alban A, Keiding H, Søgaard J. Guidelines for Socioeconomic Analyses of Pharmaceuticals. Copenhagen: Danish Ministry of Health, March 1998.
6. da Silva Alves E, Pinto Gouveia C, Sampaio C, et al., Methodological Guidelines for Economic Evaluation Studies of Medications. Lisbon: INFARMED, November 1998.
7. Dutch Pharmacoeconomic Guidelines. Draft. Pharma Pricing Review. 1999; 4: 66–68.
8. Mishan EJ Cost-benefit analysis. 4th ed. London: Unwin Hyman; 1988.
9. Kaldor N. Welfare propositions of economic and interpersonal comparisons of utility. Economic J. 1939; 49: 549–552.
10. Hicks JR The foundation of welfare economics. Economic J. 1939; 49: 696–712.
11. Gold MR, Siegel JE, Rüssel LB, et al., Cost-effectiveness in health and medicine. New York: Oxford University Press; 1996.
12. Drummond MF, O'Brien B, Stoddart GL, Torrance GW Methods for the Economic Evaluation of Health Care Programmes. Second edition. Oxford: Oxford University Press; 1997.
13. Rawls J. A Theory of Justice. Cambridge: Belknap Press of Harvard University Press; 1971.
14. Ontario Ministry of Health. Ontario Guidelines for Economic Analysis of Pharmaceutical Products. Toronto: Ontario Ministry of Health; 1994.
15. Department of Health, Housing and Community Services. Guidelines for the Pharmaceutical Industry on Preparation of Submissions to the Pharmaceutical Benefits Advisory Committee. Canberra: Commonwealth of Australia; 1995.
16. Pharmaceutical Research and Manufacturers of America. Methodological and conduct principles for pharmacoeconomic research. Drug Benefit Research. 1996; 8: 28–32.
17. Maynard A. Economic evaluation techniques in healthcare. Reinventing the wheel? Pharmacoecon. 1997; 2: 115–118.
18. Freemantie N, Drummond M. Should clinical trials with concurrent economic analyses be blinded? JAMA. 1997; 277: 63–64.
19. Buxton MJ, Drummond MF, van Hout BA, et al., Modelling in economic evaluation: an avoidable fact of life. Health Econ. 1997; 6: 217–227.
20. Drummond MF, Davies L. Economic analysis alongside clinical trials: revisiting the methodological issues. Int J Technol Assess Health Care. 1991; 7: 561–573.
21. ICH. Consensus Conference. Statistical Principles for Clinical Trials. Geneva, Switzerland: ICH; January 1997.
22. Koopmanschap MA, Rutten FFH, van Ineveld BM, et al., The friction cost method for measuring indirect costs of disease. J Health Econ. 1995; 14: 171–189.
23. Johannesson M, Karlsson G. The friction cost method: a comment. J Health Econ. 1997; 16: 249–255.
24. Liljas B. How to calculate indirect costs in economic evaluation. Pharmacoecon. 1998; 13: 1–7.
25. Department of Health, Housing and Community Services. Manual of Resource Items and their Associated Costs. Canberra: Commonwealth of Australia; 1995.
26. Johannesson M, Meitzer D. Some reflections on costeffectiveness analysis. Health Econ. 1998; 7: 1–7.
27. Keeler EB, Cretin S. Discounting of life-saving and other nonmonetary effects. Manage Sci. 1983; 29: 300–306.
28. Lipscomb J. Time preference for health in cost-effectiveness analysis. Med Care. 1989; 27: S233–253.
29. Viscusi WK, Moore M. Rates of time preference and validation of the duration of life. J Public Econ. 1989; 38: 297–317.
30. Parsonage M, Neuburger H. Discounting and health benefits. Health Econ. 1992; 1: 71–76.
31. Krahn M, Gafni A. Discounting in the economic evaluation of health care interventions. Med Care. 1993; 31: 403–418.
32. Olsen JA On what basis should health be discounted? J Health Econ. 1993; 12: 39–53.
33. Lipscomb J. Time preference for health in cost-effectiveness analysis. Med Care. 1996; 34: DS119–123.
34. Johannesson M. On the discounting of gained life-years in cost-effectiveness analysis. Int J Technol Assess Health Care. 1992; 8: 359–364.
35. Gafni A. Time in health: can we measure individuals’ “pure time preference“? Med Decision Making. 1995; 32: 31–37.
36. O'Brien BJ, Drummond MF, Labelle RJ, et al., In search of power and significance: issues in the design and analysis of stochastic cost-effectiveness studies in health care. Med Care. 1994; 32: 150–163.
37. Briggs AH, Wonderling DE, Mooney CZ Pulling cost-effectiveness analysis up by its boot-straps: a non-parametric approach to confidence interval estimation. Health Econ. 1997; 6: 327–340.
38. van Hout BA, Al MJ, Gordon GS, et al., Costs, effects and C/E ratios alongside a clinical trial. Health Econ. 1994; 3: 309–319.
39. Wakker P, Klaassen M. Confidence intervals for cost-effectiveness ratios. Health Econ. 1995; 4: 373–382.
40. Willan AR, O'Brien BJ Confidence intervals for cost-effectiveness ratios: an application of Fieller's theorem. Health Econ. 1996; 5: 297–305.
41. Laska EM, Meisner M, Siegel C. Statistical inference for cost-effectiveness ratios. Health Econ. 1997; 6: 229–242.
42. Briggs A, Sculpher M. Sensitivity analysis in economic evaluation: a review of published studies. Health Econ. 1995; 4: 355–371.
43. Drummond MF, Jefferson TO Guidelines for authors and peer reviewers of economic submissions to the BMJ Economic Evaluation Working Party. Br Med J. 1996; 313: 275–283.
44. Jefferson TO, Smith R, Yee Y, et al., Evaluating the BMJ guidelines for economic submissions: prospective audit of economic submissions to BMJ and the Lancet. JAMA. 1998; 280: 275–277.